These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11496467)

  • 21. PBS reform - a missed opportunity?
    de Boer R
    Aust Health Rev; 2009 May; 33(2):176-85. PubMed ID: 19563306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Menkes DB; Woodall AA
    N Z Bioeth J; 2003 Oct; 4(3):22, 24-5. PubMed ID: 15597480
    [No Abstract]   [Full Text] [Related]  

  • 23. Value-Based Pricing for Drugs: Theme and Variations.
    Kaltenboeck A; Bach PB
    JAMA; 2018 Jun; 319(21):2165-2166. PubMed ID: 29710320
    [No Abstract]   [Full Text] [Related]  

  • 24. Trans-Pacific trade pact triggers fears over drug prices.
    McCall C
    Lancet; 2015 Jun; 385(9986):2450-1. PubMed ID: 26122057
    [No Abstract]   [Full Text] [Related]  

  • 25. The pricing of statins and implications for Pharmaceutical Benefits Scheme expenditure.
    Clarke PM
    Med J Aust; 2013 Mar; 198(5):260. PubMed ID: 23496399
    [No Abstract]   [Full Text] [Related]  

  • 26. [The patient is without rights if the drug company is not included in the pharmaceutical insurance].
    Eklund J
    Lakartidningen; 2013 Nov 6-12; 110(45):2005. PubMed ID: 24364190
    [No Abstract]   [Full Text] [Related]  

  • 27. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 28. The need for health care reform.
    Mossinghoff GJ
    Health Syst Rev; 1994; 27(3):5-6. PubMed ID: 10134516
    [No Abstract]   [Full Text] [Related]  

  • 29. Good science and the marketplace for drugs: a conversation with Jean-Pierre Garnier. Interview by John K. Iglehart.
    Garnier JP
    Health Aff (Millwood); 2003; 22(4):119-27. PubMed ID: 12889759
    [No Abstract]   [Full Text] [Related]  

  • 30. Government commitment and regulation of prescription drugs.
    Frank RG
    Health Aff (Millwood); 2003; 22(3):46-8. PubMed ID: 12757271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health care reform and the pharmaceutical industry.
    Mossinghoff GJ
    Health Care Manag; 1994 Aug; 1(1):187-96. PubMed ID: 10152353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Woolner D
    N Z Bioeth J; 2003 Oct; 4(3):22, 25-6. PubMed ID: 15597481
    [No Abstract]   [Full Text] [Related]  

  • 33. Australia amends its free trade deal with US to lessen effect on drug costs.
    Burton B
    BMJ; 2004 Aug; 329(7463):420. PubMed ID: 15321891
    [No Abstract]   [Full Text] [Related]  

  • 34. Medicine and the pharmaceutical industry: what's right, what's wrong, and what's to come.
    Tan SY
    Singapore Med J; 1998 Mar; 39(3):91-5. PubMed ID: 9632964
    [No Abstract]   [Full Text] [Related]  

  • 35. "Tough but fair"? The active management of the New Zealand drug benefits scheme by an independent Crown agency.
    Davis P
    Aust Health Rev; 2004 Nov; 28(2):171-81. PubMed ID: 15527397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PBMs' rebate income threatened by lawsuits and move to generics.
    Sipkoff M
    Manag Care; 2008 Mar; 17(3):11-2. PubMed ID: 18447152
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharma 2020--An Economist Conference Shaping the Future of the Pharmaceuticals Industry.
    Kibble A
    IDrugs; 2008 May; 11(5):331-3. PubMed ID: 18465672
    [No Abstract]   [Full Text] [Related]  

  • 38. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 39. Issues in mandatory economic assessment of pharmaceuticals.
    Bloom BS
    Health Aff (Millwood); 1992; 11(4):197-201. PubMed ID: 1483640
    [No Abstract]   [Full Text] [Related]  

  • 40. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.